HUE031701T2 - Plazma kallikreint gátló peptidek szembetegségek kezelésében történõ alkalmazásra - Google Patents

Plazma kallikreint gátló peptidek szembetegségek kezelésében történõ alkalmazásra Download PDF

Info

Publication number
HUE031701T2
HUE031701T2 HUE07005182A HUE07005182A HUE031701T2 HU E031701 T2 HUE031701 T2 HU E031701T2 HU E07005182 A HUE07005182 A HU E07005182A HU E07005182 A HUE07005182 A HU E07005182A HU E031701 T2 HUE031701 T2 HU E031701T2
Authority
HU
Hungary
Prior art keywords
phe
cys
arg
gly
glu
Prior art date
Application number
HUE07005182A
Other languages
English (en)
Inventor
Pierre Belichard
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of HUE031701T2 publication Critical patent/HUE031701T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (4)

  1. PLAZMA KALLIKREINT GÁTLÓ IT.PTlOLb. SZEMBETKOSÉCKK KEZELÉSBEN TÖRTÉNŐ ALKALMAÄABRA SaafeMalmógéaypomok Á, Legalils «gjo fkaíns isii ÂésràÂiiifîïiAKâsï« llÿiîA tesiésí Igénylő menbtyfeesn T. Az 1 igénypont sSerinti késAtntèxy, Ms peptkl KiotiG-iksnîéîApoi^epîki :|, Αχ I. Hf 2.5*ëïivi>ôaPs««À{ôj Msbtonby azbtí^ AísgistáfAXök ^ksIssxlsiSv téti 8 pepii!^mi^ábaA #£blja s kôŸÂxsl SFQ ÎO NO. s szerinti snlneAsv-szekveEidá!: Xsai X«s2 Xaa3 X»a4 Cys Xsab Xas? XàaS -XaA# Xmm-M&amp;zn Gfy mrnU COMMIS XaMS XaelO XmM WI &amp;S XsÆ X«a24 Xaa2S Xaa26 Xa*27 Xaa2S$ Xa:G§ Cy:s KwM Xmt2 f%*'Vw»4 X&amp;;d> (%||ήί«ΛΗ« Xaa4i Xto42 Xaa4> X«â44 Xsa-lS Xa&amp;4o Xo«42 Ä4S Xaa4# Xa<O0 Gvs Xsn52 Ä53 »14 m £1« Xsï.aS'i Xaa58, ahol anodm Sa» jelentése, Á; J< 3i iïffeÿpôig SS®Âb! MibpiiGty; M: ÁI:ASí«^l09g:8Í ií^líSlmamm, ##!!§: «|| Xaa 18 jelentése a következők alkotta cséfonOól vüasxtou amatusas! és OiS; XaaH l jelentése a következők alkotta stsoponoèi valas/ton atvosKtsav·: Αόρ> Öltő Sér. Mal; Astg IfeXbépTIrH XausJ 3 jelentése a kôvetk-zOk alkotta csnpertbo! v&amp;assseri arafcsosaM. $&amp;&amp; IM, AÍ> Olyl Lys ês Gb. Xssî? ielettîese a következők alkotta cvpooôb v4b'.ztou.tnuno.>,H Arg iv\ Alp Vt, G K. Met, UoveGio :l^#PeRÄiÄwfeÄ:ÄÄÄpob^l Gly, Ser, Asp#â«nz ΆΜΊ jebsöisBäÄ váfesstöttnmmossv; Als< Asn, Ser, île, Oly, Vai, Gin és Thr, ÄtTS jebttÄmköveilBAtkÄ Le· y Gin G Als, ÄH# jelsnlbíss MveilazikslÍölia es®|s>A6ái: vâiasgîoÉÀAÛnnssv: PbA Gin* Len, Âm èsileî Äbl jefenti4eia::Âe&amp;^fe;iÂÉi::8sepEaÔ vâlasstsÂtnAÂnssv' ftp, IMyïyr* Hl is Fáj Xsss22 jelentése s kOveîkezôk alkotta csoportból választott æMtosav: Tyr és Phe; Xsa23 jelentése a következők alkotta csoportiéi választott annrwmvc Tyr <b î*he; ΧδίόιΙ jpttOiMe 8 követkÄk aikoifia Gltk Αφ£1ξ$8* A0k MbiMtl T-Ol,. Ifeés»,: XaaÁÁ jiienilse b k%ÄÄ;i!k<Ä· MMösMVt óik Gil ΑΜΑρ,ΤΟ'Α Tiki bélAliG Ab, Gives Val; X «.alt jelentése a követ* ez Ok alkut ta evoportből vábvjaurt &amp;sv.í\oiav.t Tilt, He, Ser. Vak Ab, Assx, Gly # iso; Xnaty jebotéve &amp; következők alkotó csapanbéí válavstntt sa»mo&amp;avi: Tÿl Tï|kek Fixe; XsalF jolooiévo a követkszók alkotta evopofthOI vslsíseto-t ttsninmmi Gip, Gly; Afe, :Ser# Akpi: XáaÁl jOlsoiese a követkeaök alteta evttpoftbul vlbeson atntnèÂ' Xaa42 jolesxtise a követkesOk alkotta cst^jortbol válsvstott aoHwmt. .0¾¾ ce Gly; Xsa45 ideoítHe b követi'e?0k slko-te. <; seyeAbói válsvznnt a;nmo&amp;av: Pbe ét Tyr; x .J. í \ G \vk ^ »< \<G< \ INT u \ ’- \ Γ \ Gv \,-il k^4' X i~* ‘V, ^ '' \su4'L \v%V\ Xj-1^5 λ \or>* ohrve\e v^okuoC hJ^î *t"xmî% Xiî'iiXv ouros«'«'
  2. 5. Aï t -ï. îgtuvpoî.ïjok nsi'sneivAo ''ív) '» ' "Au s ό ' v'i.<h<'t> »vet* okainr^Pna &amp;*Α <' j\ytk * kOv, V«? C'ív Ak««v v.\ >po «' M V wto* Met Bk Set .PI» Cys AS« Ph» Ly» Als Asp Asp Gly Fm Cys Arg Tip PhePbe Äs» 11« Phe Thr Arg Ql» (¾1¾ Oly 01m Phe Ile Tyr Oîÿ Oîy Cys 01» Qly As» Ql» As» Arg Phe öl» $»* Le» Ql« 01« Cys Lys Lys Mer Oys Tkf Arg Asp ©EQ10 Ho: <% Me? ills Ser Pius Cys Als Pise Lys AIsXmIÖ .Emil Gly Xsal3 Cys XasrIS X&amp;aMXsM? XsrdAXä« 1$ Arg XsssSl Pfee Plie As» Ik Phe TlvtArg Gk Cys XaaTl Xhe32 Fhe Xae34 X»s3S öly Gly Cys X#s3P Giy M»:QbÁ»y'Arf:#B^iök^er:LekQföiQlő'QyS'Ly$ Lys Mëî €&amp;·Ί® Arg Asp <SEQ ID NC3L kiét His Ser Pise Cys Ak Piss tvs Als Asp Asp öly His Cys Lys Ak Ass Hk Gin At g Phe Phe Phe As» .11« Phe Thr Arg Q1» Cys Ok Glu Pire Thr Tyr City Gly Cys Oly Oly Ash Gk Ash Arg Pise Gk Ser Lp» Ql» 01« (¾¾ Lys Lys Met Cys Thr Arg Asp (SEQ © Mo: 3), Met Ük Ser Pire Cys Ak Phe Lys Als Asp Asp Qty His Cys Lys Al» Ass Bis 01« Arg Phe Pire Pi» As» lie Phe Thr Arg 01« Cys Gl» ÖJ» Phe Thr Tyr Gly Gly Cys Als Gly Ass Gbr Asn Arg Phe CI» Ser Lesi Gl« Gl« Cys Lys Lys Met Cys Thr Arg Asp ©EQ © Mo;6 ), Met Hk Ser Phe (¾¾ Als Phe Lys Ak Àsp Asp Gly His Cys Lys Ak Ser Leu Pro Arg Phe Phe Phe Asn lie Phe Ihr Arg Gl« Cys Glu Gl« Flur lie Tyr Gly Gly Gye Gly Gly As» Gt» Asn Arg Phe Glu Ser Lee Glu Ole Cys Lys Lys Met Cys Thr Âsg Asp (GBQ IB HO:?)., Met Bis Per Phe Cys; Ak Phe Lys Ak Asp Asp Gly H rs Çys Lys Ak As« HkGift Arg Pire Phe Phe Asn il« Phe Thr Arg Gl« Cys Gl« G1« PheSer Tyr Gly Gly Cys Oiy Gly As» Gin As» Arg Phe Gl« Ser Ixe Ohr öle Cys Lys Lys Met Oys Thr Arg Asp (SBQ ID üo:BL Met Hrs Ser Phe (¾¾ Als Phe Lys Ala Asp Asp Gly His 1¾¾ lys Gly Als Bk Leu Arg Phe Phe Phe As« Ile Phe Thr Mg Gl« Cys Ghr Glu Phe Ile Tyr Giy Gly 0© Ghr Gly Am Girr Asrt Arg Phe Ghr $er Le« Ghr Ghr Cys Lys Lys Met Cys Thr Arg Asp {8EQ10 No;«)y Met Bis Ser Phe (¾¾ Ak Phe Lys Als A$p Asp Giy Arg Cys Lys Gly Ala Mis Leu Arg Phe Phe Phe As« lie Phe Thr Arg Glu Cys Gl« Glu Phe 11« Tyr Giy Gly Cys Glu Gly As« Gl« As» Arg Phe Gl« Ser Leu Gl» Glu Cys lys Lys Met Cys Thr Arg Asp CSEQ ID HG; io), Met Hk Ger Phe Oys Ak Phe:Oys Als Asp Gly Gly Arg Oy« Arg Gly Ak Hk Fr» ArgTVp Phe Phe As« Ife Phe Thr Arg Gl«. Oys Glu Gl» Phe Ser Tyr Giy Gly Cy» Gly Gly As« Gin Aon Arg Phe Glu Serie« Glu Ghr Cys Lp Lys; Met Cys Th r Arg Asp ©BQ ID NQx n), Met Bis Ser Phe Cys Ak Phe Lys Ak Asp Asp Gly Pr« Cys Arg Ak Ak Bk IT« Arg Typ Phe Phe As» lk Phe Thr Arg Ghr €ys Glu Glu Phe Ser Tyr Gly Gly £%a Gly Gly As« Glu As« Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg. Asp (SEQ ID NOna), Met Hk Ster-Phs Oys Ak Phe Lys Ak Asp Val Gly Arg Oys Arg Gly Ak Bk Pm Arg Trp Phe Phe As« II« Phe Ihr Arg Gl« Cys Glu Ghr Phe Ser Tyr Giy Gly Cys Gly Gly Ass Glu As» Arg Phe Girr Ser Leu Gl« Glu Cys Lys Ly« Met 1¾¾ Thr Arg Asp (SEQ 113 BO: J3l» Met Bis Per Phe (¾¾ Ak Ph« Lys Ak Asp Val Giy Arg Gys Arg Gly Ala Gin Pro Arg Phe Phe Phe As» lie Ehe Thr Arg Ghr Cys Glu Glu Phe 8er Tyr Giy Gly Cys Gly Gly As» Glu As» Arg Phe Glu Ser tm G&amp; Glu Cp Lys Lys Met Cys Thr Atg Asg ©BQ 10 MC: uX Met Bis Ser Phe Oys Als Phe Ly» Ala Mp Asp öly Ssr Cys Arg Ala Alá : Hls Phe Phe As« île Fis« Thr Arg 01« 1¾¾ Gk Gl« Phe Ser Tyr Oly Gly Cys Oly Oly Aan Gk As« Arg Phe Gk Sár Len 01« Gk Cys Lys X^s Me* Cys Ikr Arg Asp piQ m Keutg}, Met Bis Ser Pise Cys Ala Fee Lys Ais Gk Gly Oly Ser Oys Arg Ala Ala HG Oie Arg Typ Fis« Fhe Ass Ue Fhe Thr Arg Gk Cys Gk 01« Fis« Ser Tyr Gly Gly Cys Gly Gty Aan Gk As« Arg Phe öl« Ser In« Gk Glu Cys Lp L>« Met Cys Thr Arg Asp (SEQ ID MGnG), M«t His Ser Phe Cys Ala Pkt Lys Ala asj* Asp Gly Pro Cys Arg Oly Ala MsTAtä Arg FM Phe FM Asn He Phe Tltr Arg Gk Cjß Glu Olo Phe Ser Tyr Oly Gly %y;<ly Gly Aso Gk As« Arg Phe Glu Ser Leu Glu Glu Oys Lys Lys Met CH« Thr Arg Asp (SEQ ID MO; r?L Met Hk Ser PheGys Ala Ehe ! .$&amp; Ala AspAsp Gly Hk Cys Arg Gly Ala Leu IPro Arg Τφ· Phe Phe Ase Ile Fhe Thr Arg Glu Cys Glu Gly Phe-Se? Tyr Gly Gly Cys Oly Gly Aas Gl« As« Arg Phe Gl« Ser te» Glu Glu Cys Lys LpMel (¾¾ Thr Arg AsgCSEQTG NGaSI* Met Bis Ser Phe Qss Ala Pb« Ly» Ala A$p Ser Gly As« Arg Gly Afa Leu Pro Arg fÄ Phe Phe As» Ile Phe Thr Arg Gk Cys Glu Glu Fhe Ser Tyr Gly Gly Oys Gly Gly As« Gl« As« Arg Phe Gl« Ser Leu Glu Gla Cys Lys Lys Met Cys Thr Arg Asp (SEQ 10 NÖttp), Met HA Ser Phe (¾¾ Ala Phe Lys Ala Áep Ser Oly Atg Cys Arg Gly As« Häs Gl« Arg Phe Fhe Fhe Ass He Phe Thr Asg Gk €ys Glu Glu Phe Ser Tyr Gly Gly Oys Gly Gly Ae« Gk Arts Arg Fhe Ohs Ser Leu Glu 01« Cys Lys Lye Met Cys Thr Arg Asp (SBQ ID NCLsty}, Met Hk Ser Phe Cys Ala Ph« Lye Ala Mp Gly Gly Arg Qye Arg Ala He Gl« En» Arg Tor Phe Phe As« II« Fhe Thr Arg Ohr Cys Glu Gk Phe Ser Tyr Oly Gly Cys Gly Gly As« Gin As« Arg Fhe Glu Ser Leu Gl« Gl« Cys Lys Lp Met Cys Thr ArgAsp {SEQ ID B0;2tL Met Hk Ser Fhe Cys Ala Phe Lys Ala Asp Mp-Gly Arg Cys Arg Gly Ala Hk Fm Arg Trp Fhe Phe As« Ile Fhe Thr Arg Gk Cys Glu 01« Fhe Ser Tyr· Gly Gly Cys Gly Gly As« Gk As« Arg Phe Glu Ser Leu Glu Glu Cys Lp lys Met GpThr Arg Asgr (SEQ 10 KÖ;;3.a). Gk Ala Mel Hk Ser Fhe Cys Ala Phe Lys Ala Asp Asg Oly ITn %s Arg Als Als Hk Pro Arg Trp Phe Phe Mo II« Fhe Thr Arg Gl« Cp Gk Gl« Pha II« Tyr Gly Oly Oys Ghs Gly As« Gitt As« Arg Fhe Gk Ser Leu Gk Gk Cys« Lp Lp Mk $ß Thr Arg Aap (SEQ 10 HOtasX Gk Ak Met Bk Ser Fhe Cys Ala Fhe Lys Ala Kaato Xaats Gly Aaap Cys Aaarg XaaiA Kast? XaatS Xasp Arg Xsass Phe Phe As« Ile Phalbr ArgGk CysX'aasu AAaga Fhe AaMM XatsgS Gly Gly Oys X;«p« Gly As« Gk As« Arg Fhe Gk Ser Leu Glu Gk Cys Lys Lys Met Qp Th r Arg Asp (SEQ i 0 HOrag), Glu Ala Met Bia Per Fhe Oys Ala Fhe Lys AJa Mp Asp Gly Fm Cys Lys Ala Mm Hls Leu Arg Phe Fhe Fhe As« Ile Fhe Thr Mg 01« Cys Glu Glu Phe Ser Tyr Gly Gly Cys Gly Gly As« Glu As« Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Alst Cys Thr Arg Asp (SEQ ID NO:as), Gut Als Met Bis Ser Fhe Cys Als Fhe Lys Als Mp Mp Gly His Cys Lys Als As« Hls Gk Arg Fhe Fhe Fhe Am Oe Fhe Thr Arg Gk Cys Glu Gk Phe Thr Tyr GlyGiy Cys Gly Oh' As« Glu Ám Árn FheOks Ser Leu Gk Gk (¾¾ Lys Lys Met Cys Thr Arg Asp (SEQ H> HÖ.»6), FhelysAfci Asp Asp Gly H« Oys Lys Âk Am HIs Ob Phe As» Ik Phe Thr Arg Gl» Cys Giu Gin Phe Thr Tysr Oly Oly Cys Alá Oly M:Ä MM.M$ Ä Ok $if I« Gla Ok Cyx Lys Lys Mk Cys Ihr Arg Asp {SEQ IP 10Λ 01« Ale Met Hls Ser Phe Cys Alá Phe Lys Aie Asp Ayp Oly Hk Cys Lys· Alá Ser Le« ΡΦ ArgS« Phe Phe .As» Ik Phe thr A*g Ole Cys Gl» Ok Phe Ik t^r Oly Oly Cys Oly Oly As« Gl« Aso Ar§ Phe Ok S«r Le« Ole Ol« 0y§ Lys Lys Met Oys Tltr Arg Asp (SEQ IP 1Ä Giu .Ala Mel Bk Ser t%e Cys Als Phe Lys AI« App Asp Oly Hls Oys Lys Ak Ae« Hls Ol« Arg Phe Phe Phe As« Ile Phe Ihr Arg Ol« %s GJ« Ol« Phe Ser Tyr Oly Oly (As Oly Oly As» Ol» As» Aïg PHe Ol« Ser Let} Ok Gl» Cys Lys Lys Met 1¾.¾ The Arg Asp (SEQ IP ÄkPlr Olw Ak Alet Hk Ser Phe Oys Ale Phe Lys Ala Asp Ásp Oly Hk Cys Lys Oly Als Hk Le« Arg Pltg Phe Phë As» Ile Pi»** Thr Arg 01« CysGk 01« Phe He Tyr Oly Oly-Oys 01« Oly Ass Ob Ass Arg Phe 01» Ser Peso Ok Gl» Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID Ok Ala Met Hk Ser Phe Oys Ala Phe Lys Ala Asp Asp Gly Arg Cys lys Oly Ala Hk Le« Arg Phe Phe Phe As« Ile Phe Thr Arg Ols (¾¾ Gl« 01« Phe Ile Tyr Oly Gly Oys Ole Oly Ass 01» Cys Thr Arg Asp (EËQ IP HCk;íxL 01» Als Met Hk Oer PheOys Ala Phe Lys Ala Asp Gly Gly AtgCys Arg Oly Ali Tik FA? Arg Trp Phe Phe As« Ile Phe Thr Arg Gl« Cys Ol« Ohs Phe Ser Tyr Oly Oly Cys Gly Oly As» 0!« Ás» Asg Phe 01« Ser let:; 01» 01« Cys Lys Lys Met üya Thr Arg Asp (SEQ II) HCngâh 01» Ala Met .Hls Ser Phe (¾¾ Aie Phe Lys Ak Asp Aâ|> Gly (ko Cys Arg Als Als Hk Pm Arg Υφ Phe Phe As« II« Phe Thr Arg 01« Cys Ohr 01» Phe Sis' Tyr Oly Oly Cys Oly Gly As» 01» As« Arg Phe 01« Ser Le« 01« Gl« Cys Lys Lys Met Cys Thr Arg Asp (SEQ ID O0;33h 01« Al« Met Hk Ser Phe Oys Ae Phe Lys Ala Asp Val Gly Arg Cys Arg Gly Ala Hk Pro Arg Ttp Phe Phe Ae» II« Phe Thr Arg 01» Cvs Gl» 01» Phe Ser Tyr G'ly Oly Cys Oly Gly As» 01» As« Arg Phe Glu Ser !.«» 01» 01« Cys Lys Lys Met Cys 'Ihr Arg Asp (SEQ ID 00:34). 01« Al» Met Hk Ser Phe Cys Ai» Phe Lys Als Asp Val Oly Arg (¾¾ Arg Gly .Ala 01» Pr« Arg Phe Phe Phe Asn Ik Phe Thr Arg Gl« Cys 01« Ok Phe Ser Tyr Gly Oly Cys Gly Oly Ass 01« As» Arg Phe Gl« Ser Le« Gl« 01» Cys Lys Lys Met Oys Thr Arg Asp (SEQ ID NO:;bK 0!« Ala Met Hk St«· Phe Cys Ala Ehe Lys Als Asp Asp Gly Ser Cys Arg Ala Ala Hk Leu Arg Trp Phe Phe As« Ile Phe Thr Arg Gl« Cys Gl« Gl« Phe Set Tyr Gly Gly Cys Oly Oly As» Gl» As« Arg Phe Gl» Ser Leu Gl» Gl« Cys Lys Lys Met Cys Thr Arg Asp (SEQ II) NChgS), Glu AM Met His Ser Phe Cys Als Phe Lys Ale Glu Oly Oly Sur Çÿ* Arg Ala Ak Hk;G!« Agg Tip Pás Phe Ass Me Fhe Thr Aig Gift Cye Ola Ok Phe Su? Tyr Oly Oly Gye Oly Oly As» GM Ash Arg f ie ilu Ser Le« Ok Oki Gye Lp Lp Me* Cp Thr Arg Aspr (SËQ10 NÖ;3?L Öiu AÍS :Mht His Ser Fhö Cys Ala fhe Lys Ak Asp Asp Oly Pr» Cys Arg ßiy Ais Ok Lp Arg Phe Fhe Phe Am 8ß Phe Thr Arg Ok Cys 01« Gl« Pha Ser Tyr Gly Öiy CysölyGly i&amp;m Ol« As« Arg Phe Oki Ser Leu Gl» 01« Op hys Lys MP Cys Thr Aig Asp (SSQ ID ML38L 01« Ai« Met H»s Ser Phe 0¾¾ Ak Phe Lys Aie Asp Asp Oly Hss Cys Arg Oly Ak Le« Pt« Arg. Trp Phs Phe As« II« Phe Thr Arg Glu Cys 01« Gl« Phe Ser Tyr Gly Giy Oys Gly Oly Ar« 01« As« Arg Phe öl« Ser Le» 01« 01« Oys Lys Lys MG Cys TI«· Arg Asp (81¾ ID Gl» Als Met His Ser Phe tlyu Ak Phe Lys Als Aep Sí«' Oly As« Cys Arg Oly As» Irr» Pro .Arg Pha Phe Phe Ast? Oe Phe Thr Arg Ol« Cys öl« Ol« Phe Ser Tyr Oly Oly Oys Oly Oly Ass Gin Aars Arg Phe Ci» Ser Leu Glu öl« Oys Lys Lys Met Cys Thr Arg Asp (SEQ ID BOmoL Glu Ala Met Ills Ser Pire Oys Ala Phe Lys Ala Asp Ser Gly Arg Oys Arg Gly As« Bis öl« Arg Phe Phe Phe As» Ile Phe Thr Arg Gl« (¾¾ Glu Glu Phe Ser Tyr Oly Gly Cys Oly Oly As» 01« As« Arg Phe Öle Ser La« Olu Glu Cys Lys Lys Mat Cys Thr Arg Asp (SEQ IG PO;#), 01« Ala Met II is Ser Phe Cy» Ala Phe Lys Ak Asp Oly Oly Arg Cys Arg Ak Ge 01« Pi® Arg Trp Pire Phe As» Üe Phe 'Ihr Arg OS« Cys 01« Ohr Phe her Tyr Oly Oly Cys Oly 015' As« Gl« As« Arg Phe Ghr Ser La« 01« 01« Oys Lys Lys Met Cys Thr ArgAapCSEQIDNO^ä)» Olu Ala Met Hk Ser Pha Cys Ala Phe Lys Ak Asp Asp Gly Arg Cys Arg Gly Ala Bk Pro Arg Trp Phe Phe As« Ile Phe Thr Arg Gin Cys 01» Öl« Pha Ser Tyr Gly Oly Cys Oly Gly As« Glu As« Arg Pha Glu Ser Le« Glu öl« Cys Lys Lys Met Cys Thr Arg Asp (SEQ 1D NOMS)·· « V7 „«‘S 'ä 5î< X V 'm!u<s rin !\ ? «ii »k '"jtt*' » LI» τ w<, « > &amp; pep E Gk Ala Met His SerPhe t\s \h ΙΤκ 1 v? \ <„ Op Vp'«h PeOis As ^ \ks AC H» lbv> Ly upPhePhe A^ur Ik :PfeaiG«: Arg ;Ofe: Cys OM : Gl » Pire Tie: Tyr· 0 ly Gly Cys Glu Oly 'Ak GlU As«. Arg FL« öl« SO'Le» Ck Ohr : iöyasLysiLys Mer Cys T hr Arg. AspipEQIÇLMGMTL fl Aeii-A. iyé»ypeui&amp;k bármelyike verrat! kVAmCny a« o» tneghaiäweott sikaksr&amp;ráars. shö! À : perhl5ekgsagi«s«da « v vagy gyhikrllses isæeîhihet-egsêg; I! Aä I M tgeuypofitöfe Tkhaelyike szerlaih késsöhkny sa söti. megfeatäruahtt slkakraklstas: shul A saemlreiegség károsodott reuaafe-psreivabi Irtással τ agy «ttegrkkm! kapeshlgîhs, y. \λ î-S sr.éríspvr«··'! h&amp;rrnelyrO.' «renn» kés/itrr.ér.y, &amp;h<S a ssesnixsegség sxemknékhGegség. IP, Aa LA sgéaypôstok bâtrxielyike srerMt készsiméay aa ott megàakmaou slfcslkssksrss «k'È »> seembeteg.«èg œskwkikiêïaât ibglal »r&amp;gàhsn. H. A iô. 'sM ?a péptől Oki A Sa M«í Ht? Sc? Poe Cÿs Ala EhAlLysAk Asp; Ils Αρ?Βρ Pb* Phu Am îk Plie Thr Atg OIî% Cys Glu Glu Phe tic ïyr GlyGly CpBk <% Aso Gfe Ast; Arg Pire Ote Ser 1.-¾ ;. : h qKî Cy« Sl.ys Lys Met Cys Ihr Arg Asp (S£Q ID MOOT). n. Az 1-6, igàiypuïîfok Stenoeiysfe szÄts kttexteoéuy Mm nreghaSátoxott aik.am5&amp;aás;s> ahol &amp; ^S5toffg^g..r«íin5í.v^sídkklif^| foglal magába«. IT, A ígeoypete sxodrtn ktArhmsny az 0¾ ruegluhteogcTtgdkálaiaíiks'a. aaol a perfid Glu Als Mtt riss Set Pite (l.ys Alá Pisi Lyn Ai* Asp Asp Oly Pro C ys Arg Ak Ate Hk Pro Arg î rp Phe Phe A»s He tere Tlu Aiyr GI» Op Ghs 01« Hwók Tyr Oly Gly Oys Glu Gly Asu Glu ÂM Mg Phe Oh Ser Le« C«lu 01* Cvn í.ya Lys MOAp Tte Arg Asp (SEQ ID MOOT h
  3. 14. Αχ 1-13. igényposüok bármelyike sxsrirte ScêMtméay ax oit soogkatóroxoí· trlkaktioxásta, amely készítmény fsxmlógstk sóoklaíol terteíteM
  4. 15. Αχ 1-14. igónypoolok barms; y ke szetten kósxáztKtey az ou meghatározod aikairsmtestr« ahol a egy tnuAahhkiop n d komm«« O'« n>gm< r b tee-t* h> \<. *et .16, A ! S . jgêhypom aterrmr uft/ttrafen az olt tacgbdááio*«« ulhatesaz.Wa, ahol a masodiV. terópoa a kbÿtekezêk alkotta csoportból ylkskteîi: lte#ihMlk:us tempók kxereebesxsb kZóteS fthofeaytîkefé, biológiai telles rte gyôgysxeros kezelés,: Π. As M3. Igénypontok bárnrteyike szerinti készítmény &amp;z ott meghatározott alkalmazásra. aboi a. MÄÄgOT szsAlterteltnM; llH. Ai?, tgàxypont semte Stes AtetÉty íssrdstelklís Mmkeo, 11¾ Az i IS. igénypotuok bármelyike szettet tnagh«4Él^ilÂnlte^ilygÂf^lins.i^^là;:p^.tesfe§R -Mm&amp;êmstï bel egségek keze 10 sere s zolgákt győz ysxere I6à i 1 teklra.
HUE07005182A 2006-03-16 2007-03-13 Plazma kallikreint gátló peptidek szembetegségek kezelésében történõ alkalmazásra HUE031701T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26

Publications (1)

Publication Number Publication Date
HUE031701T2 true HUE031701T2 (hu) 2017-07-28

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11152204A HUE039108T2 (hu) 2006-03-16 2007-03-13 Készítmények és eljárások szembetegségek kezelésére
HUE07005182A HUE031701T2 (hu) 2006-03-16 2007-03-13 Plazma kallikreint gátló peptidek szembetegségek kezelésében történõ alkalmazásra

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11152204A HUE039108T2 (hu) 2006-03-16 2007-03-13 Készítmények és eljárások szembetegségek kezelésére

Country Status (12)

Country Link
US (3) US20070270344A1 (hu)
JP (2) JP5337493B2 (hu)
AU (1) AU2007224643B2 (hu)
CA (1) CA2646285C (hu)
DK (1) DK1854477T3 (hu)
ES (2) ES2682646T3 (hu)
HU (2) HUE039108T2 (hu)
LT (2) LT1854477T (hu)
PL (1) PL1854477T3 (hu)
PT (2) PT1854477T (hu)
SI (1) SI2374472T1 (hu)
WO (1) WO2007104541A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
CA2635588C (en) 2005-12-30 2015-11-10 Dyax Corp. Metalloproteinase binding proteins
PT1854477T (pt) * 2006-03-16 2016-11-10 Dyax Corp Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US20110262396A1 (en) * 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
PT3459564T (pt) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
ES2715379T3 (es) 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
KR20240033156A (ko) 2014-01-21 2024-03-12 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP6719384B2 (ja) * 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
EP3376939B1 (en) * 2015-11-18 2022-05-11 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
WO2020210368A1 (en) * 2019-04-08 2020-10-15 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
EP1489097B1 (en) * 1994-01-11 2011-10-19 Dyax Corporation Inhibitors of human plasmin derived from kunitz domains and nucleic acids encoding the same
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69533472T2 (de) * 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
CA2475382A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ES2528254T3 (es) * 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2395014T3 (es) * 2002-08-28 2013-02-07 Dyax Corp. Métodos para conservar órganos y tejidos
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20070213275A1 (en) * 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
PT1854477T (pt) * 2006-03-16 2016-11-10 Dyax Corp Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20110262396A1 (en) 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Also Published As

Publication number Publication date
AU2007224643A1 (en) 2007-09-20
CA2646285A1 (en) 2007-09-20
JP2009529553A (ja) 2009-08-20
PT2374472T (pt) 2018-08-08
US20100273721A1 (en) 2010-10-28
JP5337493B2 (ja) 2013-11-06
WO2007104541A3 (en) 2008-06-26
DK1854477T3 (en) 2016-11-28
ES2682646T3 (es) 2018-09-21
LT1854477T (lt) 2016-12-12
AU2007224643B2 (en) 2012-10-11
JP2012211194A (ja) 2012-11-01
SI2374472T1 (sl) 2018-11-30
CA2646285C (en) 2020-04-28
PL1854477T3 (pl) 2017-02-28
US9107928B2 (en) 2015-08-18
ES2601554T3 (es) 2017-02-15
PT1854477T (pt) 2016-11-10
HUE039108T2 (hu) 2018-12-28
US20070270344A1 (en) 2007-11-22
US20150368359A1 (en) 2015-12-24
WO2007104541A2 (en) 2007-09-20
LT2374472T (lt) 2018-09-25

Similar Documents

Publication Publication Date Title
CA2646285C (en) Compositions and methods for treating ophthalmic disorders
EP1755616B1 (en) Treatment of exudative retinopathy with mineralcorticoids
US20070196350A1 (en) Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
JP2007523911A (ja) 眼病変治療用テトラサイクリン誘導体
de Smet Corticosteroid intravitreal implants
US20050261243A1 (en) Antiprostaglandins for the treatment of ocular pathologies
EP2374472B1 (en) Compositions and methods for treating ophthalmic disorders
JP2007500250A (ja) 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物
AU2005232693B2 (en) Treatment of ophthalmic conditions with mineralcorticoids
WO2023144030A1 (en) Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) Biomarker for plasma kallikrein inhibitor therapy response